The Zo-NAnTax was the first clinical trial to prospectively assess the in vivo benefit of ZOL in a neoadjuvant treatment setting combined with chemotherapy and HER2-targeted therapy for HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.